title: Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
abstract: Stroke triggers a systemic inflammatory response that exacerbates the initial injury. Immunizing with peptides derived from CNS proteins can stimulate protective autoimmunity (PA). The most renowned of these peptides is copolymer-1 (Cop-1) also known as glatiramer acetate. This peptide has been approved for use in the treatment of multiple sclerosis. Cop-1-specific T cells cross the blood-brain barrier and secrete neurotrophins and anti-inflammatory cytokines that could stimulate proliferation of neural precursor cells and recruit them to the injury site; making it an ideal therapy for acute ischemic stroke. The aim of this work was to evaluate the effect of Cop-1 on neurogenesis and neurological recovery during the acute phase (7 days) and the chronic phase of stroke (60 days) in a rat model of transient middle cerebral artery occlusion (tMCAo). BDNF and NT-3 were quantified and infarct volumes were measured. We demonstrated that Cop-1 improves neurological deficit, enhances neurogenesis (at 7 and 60 days) in the SVZ, SGZ, and cerebral cortex through an increase in NT-3 production. It also decreased infarct volume even at the chronic phase of tMCAo. The present manuscript fortifies the support for the use of Cop-1 in acute ischemic stroke.
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Cruz
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Lorea
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Humberto
authors.initials: H
authors.lastname: Mestre
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Jennifer Hyuna
authors.initials: JH
authors.lastname: Kim-Lee
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Judith
authors.initials: J
authors.lastname: Herrera
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Raúl
authors.initials: R
authors.lastname: Mellado
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Vanesa
authors.initials: V
authors.lastname: Gálvez
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Leopoldo
authors.initials: L
authors.lastname: Cuellar
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México.
authors.forename: Carolina
authors.initials: C
authors.lastname: Musri
authors.affiliation: Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México, México; Centro de Investigación del Proyecto CAMINA A.C. Distrito Federal, México.
authors.forename: Antonio
authors.initials: A
authors.lastname: Ibarra
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000378:metabolism; D009414:Nerve Growth Factors / Q000378:metabolism; D055495:Neurogenesis / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects*; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D010455:Peptides; C021759:(T,G)-A-L
references.citation: Exp Transl Stroke Med. 2014 Feb 27;6(1):4
references.pmid: 24576335
references.citation: J Neuroimmunol. 2007 Feb;183(1-2):60-8
references.pmid: 17196666
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14157-62
references.pmid: 14614135
references.citation: Brain. 2002 Nov;125(Pt 11):2381-91
references.pmid: 12390966
references.citation: Stroke. 1989 Jan;20(1):84-91
references.pmid: 2643202
references.citation: ILAR J. 2002;43(4):207-13
references.pmid: 12391396
references.citation: PLoS Biol. 2010 Jun 29;8(6):e1000412
references.pmid: 20613859
references.citation: Basic Clin Pharmacol Toxicol. 2013 May;112(5):314-8
references.pmid: 23057752
references.citation: Stroke. 2007 Feb;38(2 Suppl):774-82
references.pmid: 17261737
references.citation: Stroke. 2012 Sep;43(9):2468-75
references.pmid: 22738919
references.citation: J Exp Med. 2001 Apr 16;193(8):967-74
references.pmid: 11304557
references.citation: J Neuroimmunol. 1994 Dec;55(2):195-203
references.pmid: 7530260
references.citation: Int J Stroke. 2012 Jul;7(5):378-85
references.pmid: 22712739
references.citation: J Neuroimmunol. 2013 Jan 15;254(1-2):55-62
references.pmid: 23026222
references.citation: Lancet. 2000 Jan 22;355(9200):286-7
references.pmid: 10675079
references.citation: Cereb Cortex. 2006 Jul;16 Suppl 1:i162-7
references.pmid: 16766702
references.citation: Aging Dis. 2014 Oct 01;5(5):307-26
references.pmid: 25276490
references.citation: Neurosci Lett. 2006 Oct 9;406(3):270-5
references.pmid: 16934924
references.citation: J Autoimmun. 2014 Nov;54:81-92
references.pmid: 24934599
references.citation: Neuron. 2011 May 26;70(4):687-702
references.pmid: 21609825
references.citation: Neurosci Lett. 2007 Sep 25;425(2):110-3
references.pmid: 17868996
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11784-9
references.pmid: 16864778
references.citation: Circulation. 2014 Jan 21;129(3):e28-e292
references.pmid: 24352519
references.citation: Neuroscience. 2009 Feb 6;158(3):1021-9
references.pmid: 18662748
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5172-6
references.pmid: 18362339
references.citation: J Ocul Pharmacol Ther. 2010 Feb;26(1):11-9
references.pmid: 20148653
references.citation: BMC Neurosci. 2008 Dec 10;9:117
references.pmid: 19077183
references.citation: J Neurosci Res. 2012 Mar;90(3):656-63
references.pmid: 22002544
references.citation: Nat Med. 2002 Sep;8(9):963-70
references.pmid: 12161747
references.citation: Mol Cell Neurosci. 2006 Jan;31(1):149-60
references.pmid: 16297637